6533b827fe1ef96bd1285b08
RESEARCH PRODUCT
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.
Manisha ChandaliaRizzo ManfrediManfredi RizzoGiuseppe MontaltoAngelo Maria PattiVittoria Di BartoloNicola AbateAli A. Rizvisubject
Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPilot ProjectsType2 diabetesType 2 diabetesCarotid Intima-Media ThicknessCoronary artery diseaseGlucagon-Like Peptide 1Internal medicineDiabetes mellitusLiraglutide Carotid intima-media thickness Cardiovascular risk Type2 diabetesmedicineHumansHypoglycemic AgentsProspective Studiescardiovascular diseasesProspective cohort studyGlycemicAgedOriginal Investigationbusiness.industryLiraglutideLiraglutideMiddle Agedmedicine.diseaseCardiovascular risk3. Good healthMetforminEndocrinologyIntima-media thicknessDiabetes Mellitus Type 2Cardiologycardiovascular systemFemalebusinessCardiology and Cardiovascular Medicinemedicine.drugdescription
Background Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown. Methods A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound. Results After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied. Conclusions Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations. Trial registration ClinicalTrials.gov: NCT01715428.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-02-22 |